EricISbarDO

Oncology • Collegeville, PA

Thoracic Cancer

Senior Medical Director

Join to view full profile

Dr. Sbar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sbar's full profile

Already have an account?

Office
500 Arcola Road
Collegeville, PA 19426
Phone+1 484-865-4147

Summary

I have worked in the pharmaceutical industry for 10+ years developing small molecule and immune checkpoint inhibitors in lung cancer

Clinical Expertise

Immunotherapy, Thoracic oncology, Gene Targeting, Receptor Protein-Tyrosine Kinases

Education & Training

Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Abington Memorial HospitalResidency, Internal Medicine, 1995 - 1998
Temple UniversityB.A., 1998
Philadelphia College of Osteopathic MedicineClass of 1994

Awards, Honors, & Recognition

Golden Apple Teaching Award UMDNJ - Camden Campus, 2001

Clinical Trials

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 16
Completed
Phase 3
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Start of enrollment: 2011 Dec 26
Completed
Phase 2
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Start of enrollment: 2013 May 09
Completed
Phase 3
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Rollover Protocol of Dacomitinib For Patients In Japan Start of enrollment: 2015 Jul 10
Completed
Phase 2
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Start of enrollment: 2015 Dec 18
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

755 citations
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase...
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa
The Lancet. Oncology. 2017-11-01
324 citations
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating...
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa
Journal of Clinical Oncology. 2018-06-04
46 citations
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lu...
Mario E. Lacouture, Dorothy M. K. Keefe, Stephen T. Sonis, Aminah Jatoi, Diana Gernhardt
Annals of Oncology. 2016-09-01

Research History

Medical Director - Bristol-Myers Squibb2007 - 2013

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
European Society of Medical Oncology
Member
International Association for the Study of Lung Cancer
Member
Society of Immunotherapy in Cancer
Member